Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
March 23 2020 - 9:09AM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-225230
AMENDMENT NO. 1 DATED MARCH 23, 2010
to
PROSPECTUS SUPPLEMENT DATED JULY 17, 2019
(To the Prospectus Dated June 13, 2018)
Up to $15,849,975
Common Stock
This Amendment No. 1 to Prospectus Supplement (this “Amendment”)
amends and supplements the information in our prospectus supplement dated July 17, 2019 (the “Prospectus Supplement”)
and the accompanying prospectus dated June 13, 2018 (the “Prospectus”). This Amendment should be read in conjunction
with the Prospectus Supplement and the accompanying Prospectus, and is qualified by reference thereto, except to the extent that
the information herein amends or supersedes the information contained in the Prospectus Supplement or the accompanying Prospectus.
This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement, the
accompanying Prospectus, and any future amendments or supplements hereto or thereto.
We filed the Prospectus Supplement in connection
with that certain Sales Agreement, dated July 17, 2019 (the “Sales Agreement”), by and between SVB Leerink LLC (“SVB
Leerink”), acting as the agent, and us. Since July 17, 2019, we have sold an aggregate of 630,907 shares of our common stock
pursuant to the Sales Agreement with an aggregate sales price of $5,356,401. Consequently, up to $34,643,599 remains available
for sale by us under the Sales Agreement.
We are filing this Amendment to amend the Prospectus Supplement
to provide certain information required by General Instruction I.B.6 of Form S-3. As of March 19, 2020, the aggregate market value
of our outstanding common stock held by non-affiliates, or our public float, was $47,549,925, which was calculated based on 5,185,379
shares of our outstanding common stock held by non-affiliates as of March 23, 2020, and a price of $9.17 per share, the closing
price of our common stock on February 4, 2020. During the 12 calendar months prior to, and including, the date of this Amendment,
we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3.
Pursuant to General Instruction I.B.6 of Form S-3, in no event
will we sell shares pursuant to this Amendment, the Prospectus Supplement and the accompanying Prospectus with a value of more
than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the
aggregate market value of our common stock held by non-affiliates is less than $75,000,000. As a result of these limitations and
our current public float, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock
having an aggregate offering price of up to $15,849,975 from time to time through SVB Leerink. If our public float increases such
that we may sell shares in excess of the amount reflected in this Amendment, we will file another amendment to the Prospectus Supplement
prior to making such additional sales.
Our common stock is listed on the Nasdaq Capital Market under
the symbol “IMUX.”
Investing in our common stock involves a high degree of risk.
See “Risk Factors” contained in the documents we incorporate by reference in this Prospectus Supplement to read about
factors you should consider before investing in our securities.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
SVB Leerink
The date of this Amendment No. 1 to Prospectus
Supplement is March 23, 2020.
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Apr 2024 to May 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From May 2023 to May 2024